Monopar Therapeutics announced that after a career spanning more than 35 years, Monopar’s CFO, Kim Tsuchimoto, will be retiring. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar’s Board of Directors. Monopar has been working over the past 6-plus months on a consulting basis with Karthik Radhakrishnan. Effective July 1, 2024, Mr. Radhakrishnan will be appointed Monopar’s CFO, Principal Accounting Officer, and Principal Financial Officer. Mr. Radhakrishnan has served as President and founder of Titania Partners LLC, a management consulting firm focused on the life science sector
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics reports strategic focus on radiopharma pipeline
- Monopar Therapeutics reports Q1 EPS (10c) vs. (19c) last year
- Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
- Monopar Therapeutics Advances Radiopharmaceuticals with New Patent